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A bs tr ac t
Background
The rates of death are high among patients with coinfection with tuberculosis and 
the human immunodeficiency virus (HIV). The optimal timing for the initiation of 
antiretroviral therapy in relation to tuberculosis therapy remains controversial.
Methods
In an open-label, randomized, controlled trial in Durban, South Africa, we assigned 
642 patients with both tuberculosis and HIV infection to start antiretroviral thera-
py either during tuberculosis therapy (in two integrated-therapy groups) or after the 
completion of such treatment (in one sequential-therapy group). The diagnosis of 
tuberculosis was based on a positive sputum smear for acid-fast bacilli. Only pa-
tients with HIV infection and a CD4+ cell count of less than 500 per cubic millime-
ter were included. All patients received standard tuberculosis therapy, prophylaxis 
with trimethoprim–sulfamethoxazole, and a once-daily antiretroviral regimen of 
didanosine, lamivudine, and efavirenz. The primary end point was death from any 
cause.
Results
This analysis compares data from the sequential-therapy group and the combined 
integrated-therapy groups up to September 1, 2008, when the data and safety mon-
itoring committee recommended that all patients receive integrated antiretroviral 
therapy. There was a reduction in the rate of death among the 429 patients in the 
combined integrated-therapy groups (5.4 deaths per 100 person-years, or 25 deaths), 
as compared with the 213 patients in the sequential-therapy group (12.1 per 100 
person-years, or 27 deaths); a relative reduction of 56% (hazard ratio in the com-
bined integrated-therapy groups, 0.44; 95% confidence interval, 0.25 to 0.79; 
P = 0.003). Mortality was lower in the combined integrated-therapy groups in all 
CD4+ count strata. Rates of adverse events during follow-up were similar in the two 
study groups.
Conclusions
The initiation of antiretroviral therapy during tuberculosis therapy significantly 
improved survival and provides further impetus for the integration of tuberculosis 
and HIV services. (ClinicalTrials.gov number, NCT00398996.)
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In 2007, it was estimated that there were about 33 million persons living with hu-man immunodeficiency virus (HIV) infection1 
and 9.2 million persons with newly diagnosed 
tuberculosis worldwide.2 The two diseases are 
closely intertwined, and the number of patients 
with coinfection continues to grow rapidly.3 Tu-
berculosis is the most common opportunistic dis-
ease4 and the most common cause of death in 
patients with HIV infection in developing coun-
tries.5 Notwithstanding effective tuberculosis che-
motherapy, in the presence of HIV infection, tuber-
culosis is associated with substantially increased 
case fatality rates6 and is also the most common-
ly reported cause of death in South Africa.7 In 
2007 in South Africa, an estimated 5.3 million 
people were infected with HIV and 341,165 with 
tuberculosis, of whom approximately 73% were 
coinfected with HIV.8
The optimal timing for the initiation of anti-
retroviral therapy in patients with HIV and tuber-
culosis coinfection remains unclear. Current 
guidelines are based on observational studies 
and expert opinion.9 Despite World Health Orga-
nization (WHO) guidelines supporting concomi-
tant treatment of the two diseases and urging 
more aggressive management,10 the initiation of 
antiretroviral therapy is often deferred until com-
pletion of tuberculosis therapy because of con-
cern about potential drug interactions between 
rifampin and some classes of antiretroviral 
drugs,11 the immune reconstitution inflamma-
tory syndrome,12,13 overlapping side effects,14 a 
high pill burden, and programmatic challenges.15 
This study, called the Starting Antiretroviral 
Therapy at Three Points in Tuberculosis (SAPIT) 
trial, was designed to determine the optimal 
time to initiate antiretroviral therapy in patients 




The study was an open-label, randomized, con-
trolled trial conducted at the eThekwini HIV–
tuberculosis clinic, which is operated by the Cen-
tre for the AIDS Programme of Research in South 
Africa (CAPRISA) in Durban, South Africa. This 
clinic adjoins one of the largest outpatient tuber-
culosis facilities in South Africa, the Prince Cyril 
Zulu Communicable Disease Centre.
Guidelines of the South African National Tu-
berculosis Control Programme16 stipulate that 
a first episode of tuberculosis be treated with a 
2-month intensive combination-drug regimen of 
rifampin, isoniazid, ethambutol, and pyrazina-
mide, with doses determined according to pre-
treatment weight. Thereafter, patients receive a 
4-month continuation regimen of isoniazid and 
rifampin. Patients with a history of tuberculosis 
receive a 3-month intensive regimen (including the 
addition of streptomycin for the first 2 months), 
followed by a 5-month continuation phase. In our 
study, patients were routinely offered therapy 
that was directly observed by clinic-based nurses. 
Some patients selected community-based super-
visors, heads of households, and treatment sup-
porters in workplaces who supervised and re-
corded the taking of medication.
Patients
From June 28, 2005, to July 11, 2008, we recruited 
patients who were at least 18 years of age and 
who had confirmed HIV infection (on the basis 
of two rapid HIV tests) and a positive smear for 
tuberculosis acid-fast bacilli (with the use of au-
ramine and Ziehl–Neelsen staining methods). 
Inclusion in the study required independent con-
firmation of positive tuberculosis status at the 
Department of Medical Microbiology at the Nel-
son R. Mandela School of Medicine, initiation of 
treatment with the standard tuberculosis regimen 
at the Communicable Disease Centre, a CD4+ 
cell count of less than 500 per cubic millimeter at 
screening, and an absence of clinical contraindi-
cations to the initiation of antiretroviral therapy. 
Female patients were required to agree to use 
contraception while receiving efavirenz.
Study Procedures
After providing written informed consent, patients 
with confirmed HIV and tuberculosis coinfec-
tion were randomly assigned in a 1:1:1 ratio (with 
the use of sealed envelopes) to one of three study 
groups in permuted blocks of six or nine with no 
stratification. In the first group, antiretroviral 
therapy was to be initiated within 4 weeks after 
the start of tuberculosis therapy (early integrated-
therapy group). In the second group, antiretrovi-
ral therapy was to be initiated within 4 weeks 
after the completion of the intensive phase of tu-
berculosis therapy (late integrated-therapy group). 
In the third group, antiretroviral therapy was to 
be initiated within 4 weeks after the completion 
of tuberculosis therapy (sequential-therapy group).
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All patients received adherence counseling, 
prophylaxis with trimethoprim–sulfamethoxa-
zole against HIV-related opportunistic infections, 
and the same once-daily three-drug antiretrovi-
ral therapy regimen, consisting of didanosine 
(250 mg for a body weight of <60 kg and 400 mg 
for a weight ≥60 kg), lamivudine (300 mg), and 
efavirenz (600 mg). Adherence to the antiretro-
viral regimen was assessed monthly according 
to pill counts (pills issued minus pills returned 
as a percentage of anticipated pill consumption). 
Regardless of the study-group assignment, pa-
tients could be started on antiretroviral therapy 
at any time by clinicians at the Communicable 
Disease Centre, by study clinicians, or by per-
sonal physicians at their discretion.
Follow-up visits for the monitoring of safety 
and clinical status were scheduled monthly for 
24 months. Adverse events were graded with the 
use of the Division of AIDS Table for Grading 
the Severity of Adult and Pediatric Adverse 
Events, version 1.0, as recommended by the Na-
tional Institute of Allergy and Infectious Dis-
eases (December 28, 2004). Measurements of 
CD4+ cell counts with the use of flow cytometry 
(FACSCalibur, Becton Dickinson) and HIV RNA 
(Cobas Amplicor HIV-1 Monitor, version 1.5, 
Roche) were performed at the time of screening, 
at randomization, and every 6 months there-
after. Monitoring for radiologic changes and 
sputum conversion was performed at the time 
of screening, at the end of the intensive phase of 
tuberculosis therapy, 1 month before the end of 
tuberculosis therapy, and whenever clinically indi-
cated.
End Points
The primary end point was death from any cause. 
Secondary end points included discontinuation 
because of side effects, toxic effects, HIV RNA 
levels, tuberculosis outcomes, and the occurrence 
of the immune reconstitution inflammatory syn-
drome. Discontinuation because of side effects 
was documented as study-initiated treatment in-
terruptions in the pharmacy records. Toxic effects 
were assessed by means of a clinical checklist 
and standard laboratory tests for hematologic, 
hepatic, and renal abnormalities. The immune 
reconstitution inflammatory syndrome was de-
fined as a paradoxical deterioration in clinical 
status or laboratory findings after the initiation 
of antiretroviral or antituberculosis therapy with-
out another attributable cause.
Interim Monitoring
After a planned interim analysis, on September 1, 
2008, almost 2 months after completion of en-
rollment, the data and safety monitoring com-
mittee recommended that all patients in the se-
quential-therapy group be started on antiretrovi-
ral therapy as soon as possible but continue in 
follow-up until study completion. The committee 
also recommended continuation of the two inte-
grated-therapy groups with no changes. The pa-
tients in the sequential-therapy group were con-
tacted within a week after the committee’s 
meeting, and almost all of them started antiret-
roviral therapy within a month. We present data 
up to September 1, 2008, comparing the sequen-
tial-therapy group with the combined early and 
late integrated-therapy groups, which are here-
after referred to as the integrated-therapy group.
Study Oversight
The trial was approved by the Biomedical Research 
Ethics Committee at the University of KwaZulu-
Natal and the South African government’s Medi-
cines Control Council.
Statistical Analysis
We estimated that we would need to enroll 649 
patients (factoring in an anticipated loss to fol-
low-up) in order to have a power of 80% and an 
alpha level of 0.05 to detect a 60% reduction in 
mortality on the basis of a predicted death rate of 
10% in the study group with the worst outcome. 
All analyses were performed according to the 
intention-to-treat principle. The primary outcome 
was analyzed with the use of Kaplan–Meier 
curves and the log-rank test. The duration of 
time in the study was calculated as the time from 
randomization to death, withdrawal from the 
study, or the cutoff date of September 1, 2008, 
whichever occurred first. Poisson approximations 
were used to calculate confidence intervals for 
the rate of death. Proportional-hazards regres-
sion models were used to adjust for confounding 
variables. Fisher’s exact test was used for the 
analysis of categorical data, and unpaired t-tests 




A total of 642 patients with HIV and tuberculosis 
coinfection were enrolled: 429 in the combined 
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integrated-therapy group and 213 in the sequen-
tial-therapy group (Fig. 1). At baseline, patients 
in the two groups had similar demographic and 
clinical characteristics, including age, CD4+ cell 
counts, and HIV RNA levels (Table 1).
Follow-up
At the time of the data cutoff, on September 1, 
2008, a total of 338 of the 642 patients (52.6%) 
were still in active follow-up, 52 (8.1%) had died 
during follow-up, 134 (20.9%) had completed 
follow-up, and 56 (8.7%) had withdrawn before 
study completion. Of the 62 patients (9.7%) who 
were regarded as lost to follow-up (9.6% in the 
integrated-therapy group and 9.9% in the sequen-
tial-therapy group), 35 were known to be alive, 
and the clinical status of the remaining 27 was 
unknown. (Patients were considered to be lost to 
follow-up if they went 4 months without a visit.) 
The median duration of follow-up in the trial was 
12.1 months (interquartile range, 6.1 to 21.6).
Initiation of Antiretroviral Therapy
The median duration of tuberculosis therapy was 
similar among patients who completed such ther-
apy: 210 days for 271 patients in the integrated-
therapy group and 207 days for 137 patients in 
the sequential-therapy group. At the time of this 
analysis, 102 patients in the integrated-therapy 
group and 48 patients in the sequential-therapy 
group were still receiving tuberculosis therapy.
Of the 350 patients in the integrated-therapy 
group who started antiretroviral therapy, 338 did 
so while they were receiving tuberculosis therapy. 
Patients in this group started antiretroviral thera-
py at a mean (±SD) of 70±72 days after the start 
of tuberculosis therapy. Of the 100 patients in 
the sequential-therapy group who started anti-
retroviral therapy, 7 did so while they were re-
ceiving tuberculosis therapy. In this group, anti-
retroviral therapy was initiated a mean of 260±71 
days after the initiation of tuberculosis therapy. 
Thus, patients in the sequential-therapy group 
started antiretroviral therapy, on average, 190 days 
later than those in the integrated-therapy group.
Primary End Point
There were 25 deaths in the integrated-therapy 
group, for a death rate of 5.4 per 100 person-years, 
as compared with 27 deaths in the sequential-
therapy group, for a death rate of 12.1 per 100 
person-years (hazard ratio in the integrated-ther-
apy group, 0.44; 95% confidence interval [CI], 0.25 
to 0.79; P = 0.003) (Table 2 and Fig. 2). After ad-
justment for baseline WHO status of HIV infec-
tion (stage 4 vs. stage 3), CD4+ cell count, age, sex, 
the presence or absence of a history of tuberculo-
sis, the presence or absence of extrapulmonary 
tuberculosis, and baseline HIV RNA level, the haz-
ard ratio was 0.43 (95% CI, 0.25 to 0.77; P = 0.004).
Information on the 52 deaths was based on 
hospital chart notes for 28 patients, a death cer-
tificate for 1 patient, and two independent oral 
reports of death for 23 patients. On the basis of 
the chart notes and death certificate for 29 pa-
tients, causes of death in the integrated-therapy 
group were tuberculosis (including tuberculous 
meningitis) for 2 patients, respiratory distress or 
Pneumocystis jiroveci pneumonia for 6 patients, and 
metabolic acidosis, cardiomyopathy, and a motor-
vehicle accident for 1 patient each; causes of death 
in the sequential-therapy group were tuberculo-
sis (including tuberculous meningitis) for 6 pa-
tients, respiratory distress or P. jiroveci pneumonia 
for 3 patients, and nontuberculous meningitis, 
gastroenteritis, renal failure, hepatic failure, and 
glioma for 1 patient each. The cause of death 
was unclear in the chart notes of four patients.
The baseline CD4+ cell count independently 
predicted mortality in the two study groups. Mor-
tality was lower in the integrated-therapy group 
in all CD4+ count strata (Table 2). The median 
baseline CD4+ count was similar in the two study 
groups. There was no interaction between the 
CD4+ count and the study groups (P = 0.57).
Treatment Outcomes
The rate of adherence to antiretroviral therapy 
according to pill counts was 97.2% in the inte-
grated-therapy group and 97.6% in the sequential-
therapy group. Outcomes with respect to tuber-
culosis therapy were similar in the two study 
groups, regardless of whether patients were re-
ceiving first-episode therapy or repeated therapy 
(Table 3). At 12 months after randomization, the 
proportion of patients with a suppressed HIV RNA 
level was higher in the integrated-therapy group 
than in the sequential-therapy group (90.0% vs. 
77.8%, P = 0.006). However, the proportion of pa-
tients with a suppressed HIV RNA level 6 months 
after the initiation of antiretroviral therapy was 
similar in the two groups (Table 4).
Adverse Events
The immune reconstitution inflammatory syn-
drome was diagnosed in 53 of 429 patients (12.4%; 
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130 Did not return for randomization
101 Responded after enrollment window
100 Returned for enrollment when enrollment 
was not open
91 Did not have confirmed positive smear for  
acid-fast bacilli
55 Had CD4+ count >500 cells/mm3
44 Declined participation
38 Had medical reasons
17 Planned to relocate
17 Had practical reasons
16 Declined antiretroviral therapy
13 Were receiving antiretroviral therapy
12 Had no sputum test
10 Died
6 Were not receiving tuberculosis treatment
3 Were pregnant or planned pregnancy
36 Had other reasons
429 Were assigned to integrated-
therapy group
213 Were assigned sequential-
therapy group
79 Did not initiate antiretroviral therapy
9 Died
22 Were lost to follow-up
24 Were awaiting antiretroviral
therapy




5 Could not attend visits
6 Requested withdrawal
3 Received antiretroviral therapy
elsewhere
113 Did not initiate antiretroviral therapy
24 Died
19 Were lost to follow-up




7 Could not attend visits
2 Requested withdrawal
2 Had other reasons
350 Initiated antiretroviral therapy 100 Initiated antiretroviral therapy
53 Did not complete 24-mo follow-up
16 Died
19 Were lost to follow-up
18 Were withdrawn
13 Relocated
1 Could not attend visits
4 Requested withdrawal
7 Did not complete 24-mo follow-up
3 Died
2 Were lost to follow-up
2 Were withdrawn
1 Relocated
1 Could not attend visits
94 Completed 24-mo follow-up
203 Continued in follow-up
38 Completed 24-mo follow-up
55 Continued in follow-up
1331 Were screened




627 Declined HIV testing
349 Did not return for screening visit
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Figure 1. Enrollment and Outcomes.
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95% CI, 9.5 to 15.9) in the integrated-therapy 
group and in 8 of 213 patients (3.8%; 95% CI, 1.8 
to 7.5) in the sequential-therapy group (P<0.001). 
Six patients required the use of corticosteroids 
(five in the integrated-therapy group and one in 
the sequential-therapy group). No changes in 
the antiretroviral regimen were needed because 
of immune-reconstitution events. None of the 
deaths were determined to be related to the im-
mune reconstitution inflammatory syndrome. 
Among grade 3 or 4 adverse events that were not 
regarded as immune reconstitution, 140 occurred 
in the integrated-therapy group (30 per 100 per-
son-years) and 71 in the sequential-therapy group 
(32 per 100 person-years) (P = 0.69) (see the table 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org).
Discussion
This trial showed that the initiation of antiretro-
viral therapy during tuberculosis therapy in pa-
tients with confirmed tuberculosis and HIV coin-
fection reduced mortality by 56% (95% CI, 21 to 
75). The death rate rose from 5.4 per 100 person-
years to 12.1 per 100 person-years when initia-
tion of antiretroviral therapy was delayed until 
the completion of tuberculosis therapy. The inter-
val between the completion of tuberculosis ther-
apy and the initiation of antiretroviral therapy is 
important; a considerable number of deaths in 
the sequential-therapy group occurred during this 
time (Fig. 2). Once antiretroviral therapy was ini-
tiated, however, it was associated with similarly 
high levels of viral suppression in the two study 





(N = 213) P Value
Age — yr 0.48
Mean 34.4±8.38 33.9±8.18
Range 19–72 19–60
Male sex — % 48.7 52.1 0.45
Educational level — no./total no. (%) 0.03
Primary school or less 92/427 (21.5) 48 (22.5)
Some secondary school 205/427 (48.0) 80 (37.6)
Completed secondary school 130/427 (30.4) 85 (39.9)
Employed — no./total no. (%) 251/428 (58.6) 116 (54.5) 0.35
History of tuberculosis — no. (%) 144 (33.6) 64 (30.0) 0.42
Karnofsky score — no./total no. (%) 0.44
90 or 100 251/425 (59.1) 132/209 (63.2)
70 or 80 165/425 (38.8) 75/209 (35.9)
<70 9/425 (2.1) 2/209 (1.0)
Median CD4+ count (interquartile range) — cells/mm3† 150 (77–254) 140 (69–247) 0.32
Median log viral load (interquartile range) — copies/ml‡ 5.2 (4.5–5.6) 5.2 (4.7–5.6) 0.22
WHO stage 4 HIV infection — no. (%)§ 21 (4.9) 10 (4.7) 1.00
Presence of extrapulmonary tuberculosis — no. (%) 24 (5.6) 10 (4.7) 0.71
Median no. of days of tuberculosis therapy at randomization 
(interquartile range)
9 (1–14) 9 (7–16) 0.15
* Plus–minus values are means ±SD.
† Patients underwent randomization on the basis of the CD4+ count at screening (criterion for study enrollment, <500 
cells per cubic millimeter). However, for 16 patients, the CD4+ count at enrollment was more than 500 cells per cubic 
millimeter.
‡ The viral load at baseline was measured in 397 patients in the integrated-therapy group and in 201 patients in the se-
quential-therapy group.
§ The remainder of patients had stage 3 infection, according to criteria of the World Health Organization (WHO).
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groups, findings that are similar to those ob-
served in other HIV treatment programs in South 
Africa.17
Mortality among patients with HIV and tuber-
culosis coinfection is known to be high despite 
the use of effective tuberculosis therapy.5 Obser-
vational studies have indicated that the initiation 
of antiretroviral therapy during tuberculosis ther-
apy improves treatment outcomes in such pa-
tients. A meta-analysis of studies involving 6934 
patients at five hospitals in Madrid showed a sig-
nificant improvement in survival (63% increase) 
among patients who began antiretroviral therapy 
while they were receiving tuberculosis therapy.18 
In Thailand, an analysis of 1003 patients showed 
an increase by a factor of 20 in the rate of death 
among patients who did not receive simultane-
ous antiretroviral and tuberculosis therapies, as 
compared with those who did receive the two 
therapies.19 A Thai review of studies involving 
626 patients showed a hazard ratio for death of 
0.17 for patients who started antiretroviral ther-
apy during tuberculosis treatment, as compared 
with patients who did not receive antiretroviral 
therapy.20 Although the selection of patients for 
integrated treatment by clinicians may have led 
to bias in these studies, the trials show a con-
sistent association between antiretroviral ther-
apy and survival in coinfected patients. The ran-
domized design of our trial validates and extends 
the findings from these retrospective observa-
tional data.
Among patients with CD4+ counts of less than 
200 cells per cubic millimeter, the rate of death 
was 46% lower in the integrated-therapy group 
than in the sequential-therapy group (P = 0.04). 
Although the number of deaths was small in the 
subgroup of patients who had CD4+ counts be-
tween 200 and 500 cells per cubic millimeter, 
there was a trend toward lower mortality in the 
Table 2. Death Rates and Hazard Ratios, Stratified According to CD4+ Cell Count.

























All patients 429 467 25 5.4 (3.5–7.9) 213 223 27 12.1 (8.0–17.7) 0.44 (0.25–0.79) 0.003
≤200 cells/mm3 273 281 23 8.2 (5.2–12.3) 138 137 21 15.3 (9.6–23.5) 0.54 (0.30–0.98) 0.04
>200 cells/mm3 156 186 2 1.1 (0.1–3.9) 75 86 6 7.0 (2.6–15.3) 0.16 (0.03–0.79) 0.02
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Figure 2. Kaplan–Meier Survival Curves.
TB denotes tuberculosis.
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integrated-therapy group. This finding has im-
plications for treatment guidelines and policies. 
Current WHO guidelines for the treatment of 
patients with HIV and tuberculosis coinfection 
recommend the deferment of antiretroviral ther-
apy until the completion of tuberculosis therapy 
in patients with WHO stage 3 HIV infection and 
CD4+ counts of more than 200 cells per cubic 
millimeter.3,10 Our findings suggest that this 
guideline should be expanded to include cotreat-
ment of HIV infection and tuberculosis in pa-
tients with CD4+ counts of less than 500 cells 
per cubic millimeter.
There is increasing evidence that even among 
patients with HIV infection who do not have 
tuberculosis, earlier initiation of antiretroviral 
therapy is associated with improved outcomes.21-23 
In a study involving 8362 asymptomatic patients 
with HIV infection in the United States and 
Canada,22 mortality was 69% lower among pa-
tients in whom antiretroviral therapy was initi-
ated when the CD4+ count was between 350 and 
500 cells per cubic millimeter than in those in 
whom such therapy was deferred until the CD4+ 
count was less than 350 cells per cubic millime-
ter. Similarly, data from 18 prospective cohort 
studies have shown that deferring antiretroviral 
therapy was associated with higher rates of the 
acquired immunodeficiency syndrome (AIDS) and 
death than starting therapy when the CD4+ count 
was more than 350 cells per cubic millimeter.23
However, there are major concerns regarding 
the early initiation of antiretroviral therapy during 
tuberculosis treatment, including the increased 
risk of the immune reconstitution inflammatory 
syndrome, additive toxic effects, and the poten-
tial adverse effect on outcomes of tuberculosis 
therapy. We found similar rates of grade 3 and 
4 adverse events in the two study groups and 
similar outcomes of tuberculosis therapy. Since 
many of the deaths occurred after the comple-
tion of tuberculosis therapy, the providers of such 
therapy were unaware of the benefits of cother-
apy of tuberculosis and HIV infection. Although 
the incidence of immune-reconstitution events 
was significantly higher in the integrated-therapy 
group, this finding was not unexpected, since 
such events have been associated with the early 
initiation of antiretroviral therapy in patients 
with tuberculosis.24,25 The incidence of such 
events in the integrated-therapy group was simi-
lar to that observed in studies of other cohorts 
Table 3. Clinical Outcomes of Tuberculosis Therapy.*














Tuberculosis cure† 67 (57.8) 131 (57.7) 31 (53.4) 67 (59.3) 1.00
Successful completion‡ 16 (13.8) 42 (18.5) 5 (8.6) 16 (14.2) 0.20
Therapy success (cure plus successful completion) 83 (71.6) 173 (76.2) 36 (62.1) 83 (73.5) 0.07
Died before completion of therapy 7 (6.0) 12 (5.3) 6 (10.3) 9 (8.0) 0.19
Therapy interruption 2 (1.7) 3 (1.3) 3 (5.2) 7 (6.2) 0.01
Therapy failure§ 0 0 0 1 (0.9) 0.33
Loss to follow-up 13 (11.2) 13 (5.7) 6 (10.3) 6 (5.3) 1.00
Therapy outcome unknown because of transfer  
to another clinic
1 (0.9) 5 (2.2) 2 (3.4) 1 (0.9) 1.00
Other outcome 1 (0.9) 1 (0.4) 0 0
Outcome pending (still receiving therapy at time 
of analysis)
9 (7.8) 20 (8.8) 5 (8.6) 6 (5.3) 0.49
* Only patients who were enrolled in the study at least 7 months before the date of the analysis are included. Percentages may not total 100% 
because of rounding.
† Tuberculosis cure was defined as a sputum smear that was negative for acid-fast bacilli close to the time of therapy completion.
‡ Successful completion of therapy was defined as the use of more than 85% of the prescribed medication.
§ Therapy failure was defined as the presence of a positive smear or culture for Mycobacterium tuberculosis obtained at least 5 months after the 
initiation of tuberculosis therapy.
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in developing countries,24,26 including a retrospec-
tive analysis of hospitalized Thai patients receiv-
ing both antiretroviral and tuberculosis thera-
pies, which showed that 21 of 167 patients (12.6%) 
had an immune-reconstitution event.26 However, 
none of the deaths in our trial, in which data 
regarding the cause of death were available, were 
considered attributable to the immune reconsti-
tution inflammatory syndrome. It is reassuring 
that recent studies of tuberculosis-associated 
immune reconstitution inflammatory syndrome 
indicate that this complication is rarely fatal and 
that severe episodes can be successfully managed 
with corticosteroids.27 Thus, the concern about 
increasing the likelihood of such episodes must 
be tempered by the survival benefit shown in our 
study. Nevertheless, the paradoxical deteriora-
tion in the clinical status is sufficiently com-
mon to warrant close clinical monitoring in the 
first few months after the initiation of antiretro-
viral therapy in patients coinfected with tuber-
culosis.
We acknowledge several limitations of our 
study. The use of death from any cause as the 
primary end point might underestimate the po-
tential effect of integrated HIV–tuberculosis treat-
ment on the rates of death specifically from tu-
berculosis or HIV infection. Since we were not 
able to obtain reliable information on the causes 
of all deaths in the trial, we were not able to 
estimate the effect on the rate of deaths that 
were related only to tuberculosis or HIV infec-
tion. Since our trial included only patients who 
had a positive sputum smear for acid-fast bacilli 
and whose disease was diagnosed and treated in 
an outpatient tuberculosis clinic, the results may 
not be directly generalizable to all forms and 
severity levels of tuberculosis. Since a retrospec-
tive analysis of 549 patients with AIDS and extra-
pulmonary tuberculosis showed that the intro-
duction of highly active antiretroviral therapy 
significantly improved survival,28 the early ini-
tiation of antiretroviral therapy may have similar 
benefits in patients with extrapulmonary tuber-
culosis. Although we have no reason to believe 
that our findings do not apply to sputum-smear–
negative tuberculosis, our findings require em-
pirical confirmation in this group. It should be 
noted that the judgment of study and nonstudy 
care providers took precedence over protocol-
defined timing of the initiation of antiretroviral 
therapy, which led to early initiation of such 
therapy in some patients in the sequential-ther-
apy group and delayed initiation in some patients 
in the integrated-therapy group. Another limita-
tion was the delay in the initiation of antiretro-
viral therapy after the completion of tuberculosis 
therapy in the sequential-therapy group because 
of clinical issues (e.g., elevated levels of liver en-
zymes) or missed visits. Furthermore, the ques-
tion of when antiretroviral therapy should be 
initiated during tuberculosis therapy awaits com-
pletion of the study.
In summary, our findings provide compelling 
Table 4. Clinical Outcomes of HIV Therapy.
Outcome Integrated Therapy Sequential Therapy P Value
Viral load <400 copies/ml
At 12 mo after randomization 0.006
No./total no. 199/221 70/90
Percent (95% CI) 90.0 (85.1–93.5) 77.8 (67.6–85.6)
At 6 mo after initiation of antiretroviral therapy 0.40
No./total no. 174/191 39/45
Percent (95% CI) 91.1 (85.9–94.6) 86.7 (72.5–94.5)
Mean increase in CD4+ count from baseline
At 12 mo after randomization 0.004
No. of patients 207 84
No. of cells/mm3 (95% CI) 148.7 (130.5–166.9) 100.7 (77.5–124.0)
At 6 mo after initiation of antiretroviral therapy 0.71
No. of patients 187 41
No. of cells/mm3 (95% CI) 124.2 (105.4–143.1) 116.3 (88.0 to 144.6)
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evidence of the benefit of initiating antiretroviral 
therapy during tuberculosis therapy in patients 
with HIV coinfection. The findings also support 
recommendations by the WHO and others for 
the integration of tuberculosis and HIV care.
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